GLP-1 receptor agonists are associated with a modestly increased risk of gallbladder and biliary problems — gallstones, gallbladder inflammation, and, less often, gallbladder removal (semaglutide, sold as Ozempic and Wegovy; tirzepatide, sold as Mounjaro and Zepbound). Two things appear to drive it: rapid or substantial weight loss, which is itself a long-known cause of gallstones, and a direct slowing of the gallbladder by the medicines. The key word is associated — much of the signal tracks with how fast and how much weight you lose rather than being proven to come from the drug alone. The absolute risk stays low, but it is real, and the symptoms are worth knowing. This is general information, not medical advice — talk to your prescriber about your own situation.
Why a GLP-1 can affect the gallbladder
The gallbladder stores bile and releases it to help digest fat. Two overlapping pathways help explain why GLP-1 medications are linked to gallbladder trouble.
The first is rapid weight loss, and it is not unique to these drugs. When the body sheds weight quickly, the liver releases extra cholesterol into bile and the gallbladder empties less often, so bile stagnates and stones are more likely to form. The NIDDK notes this is why rapid weight loss raises the risk of gallstones and why it recommends a gradual pace instead of crash dieting. Because GLP-1 medications can produce substantial weight loss, they carry that same well-established risk along with the loss itself.
The second is a direct effect on the gallbladder: the medicines appear to reduce how actively the gallbladder contracts, which would let bile sit longer. This reduced-motility explanation is a leading mechanistic theory rather than settled fact, but it fits the observation that risk runs higher at higher doses, with longer use, and at weight-loss dosing compared with diabetes dosing — a pattern the meta-analytic evidence below shows directly.
How common is it?
The honest answer is uncommon, but more common than placebo. Two kinds of evidence are worth separating: per-dose percentages from individual trials, and a relative-risk estimate pooled across many trials.
From the trials behind the prescribing information:
- The semaglutide (Ozempic) prescribing information reports gallstones (cholelithiasis) in about 1.5% of people at one dose and 0.4% at another, versus 0% on placebo.
- The tirzepatide (Zepbound) prescribing information reports gallstones in about 1.1% versus 1.0% on placebo, gallbladder inflammation (cholecystitis) in about 0.7% versus 0.2%, and gallbladder removal (cholecystectomy) in about 0.2% versus 0% — and notes that the acute gallbladder events were associated with weight reduction.
Pooling the bigger picture, a large meta-analysis in JAMA Internal Medicine (He and colleagues, 2022; 76 randomized trials, 103,371 patients) found GLP-1 use associated with gallbladder or biliary disease at a relative risk of 1.37 (95% CI 1.23–1.52) — roughly 27 extra events per 10,000 people treated per year. Two details matter for reading that number fairly. First, the relative risk was markedly higher at weight-loss dosing (RR 2.29) than at diabetes dosing (RR 1.27), consistent with weight loss itself driving much of the effect. Second, a relative risk is not an absolute one: a 37% higher relative risk still leaves the absolute risk low, because the baseline is small. The per-dose percentages above are observed trial rates; the relative risks are meta-analytic estimates — different kinds of numbers that point the same direction.
The symptoms to watch
A gallbladder attack has a fairly recognizable signature. Cleveland Clinic describes the classic gallbladder attack symptoms:
- Steady pain in the upper-right abdomen, under the right rib cage, often coming on after a fatty or heavy meal.
- Pain that frequently radiates to the right shoulder blade or the back.
- Nausea or vomiting alongside the pain.
- An episode that lasts a few hours rather than passing in seconds.
Mild, brief twinges are not the same thing. The pattern above — steady, located under the right ribs, lingering for hours, often after fatty food — is the one worth taking seriously.
Lowering the risk
These are typical, prescriber-directed considerations — not a prescription, and never a reason to change your dose on your own:
- A gradual pace of weight loss is the main lever. Because the risk tracks so closely with rapid loss, easing the rate helps. The NIDDK points to gradual weight loss — roughly 5–10% over about six months — and avoiding crash diets. How that pace is achieved, including any dose pacing, is a prescriber decision, not a self-adjustment.
- Stay under medical monitoring. The semaglutide prescribing information states that if gallstones are suspected, gallbladder studies and appropriate clinical follow-up are indicated — which is your clinician's call to make if symptoms appear.
- Report symptoms early rather than waiting them out, so they can be evaluated before they escalate.
For where this sits among the other serious concerns, see the serious GLP-1 risks overview, and for the full picture of expected effects, the GLP-1 side effects guide.
When to seek care
Gallbladder problems on a GLP-1 are uncommon, and most people never run into them. The reason to know the signs is simple: a gallbladder attack is one of the situations where telling the difference quickly, and getting evaluated, genuinely matters.
Frequently asked questions
Do GLP-1 medications cause gallstones? They are associated with a modestly higher risk of gallstones, not proven to cause them on their own. Much of the signal tracks with rapid or substantial weight loss — itself a long-known cause of gallstones — and the medicines may also slow the gallbladder. The absolute risk stays low.
How much does the risk actually go up? A large meta-analysis put the relative risk of gallbladder or biliary disease at about 1.37, or roughly 27 extra events per 10,000 people treated per year. It was higher at weight-loss dosing (about 2.29) than at diabetes dosing (about 1.27). Because the baseline is small, the absolute risk remains low.
What are the warning signs of a gallbladder problem? Steady pain in the upper-right abdomen under the right ribs, often after a fatty meal, frequently radiating to the right shoulder blade or back, with nausea or vomiting, lasting a few hours. Pain with fever, chills, or jaundice (yellow skin or eyes) needs urgent care.
Can I lower the risk? The main lever is a gradual pace of weight loss rather than rapid loss — the NIDDK suggests roughly 5–10% over about six months and avoiding crash diets. Pace and dosing are prescriber decisions; don't self-adjust. Staying under medical monitoring and reporting symptoms early both help.
How we reviewed this: written from authoritative sources, including the He et al. meta-analysis in JAMA Internal Medicine, the NIDDK on dieting and gallstones, and Cleveland Clinic on gallbladder disease. Per-dose rates are attributed to the semaglutide (Ozempic) and tirzepatide (Zepbound) prescribing information; see the Ozempic label on DailyMed. See our editorial and review policy and sourcing standards. Where the evidence is an association rather than proven sole causation — much of the signal tracks with the rate and amount of weight loss, and the reduced-gallbladder-motility detail is a leading explanation rather than settled fact — we say so rather than overstating it.
Every clinical claim above is cited inline to a primary source. See how we review and our sourcing & fact-check standards.